(An Autonomous Body Recognized by Ministry of Commerce & Industry, Government of India)
NeoGenomics Launches c-MET Companion Diagnostic for NSCLC
NeoGenomics has introduced the c-MET Companion Diagnostic (CDx) for advanced non-small cell lung cancer (NSCLC), delivering results within 48 hours for oncologists and pathologists. This immunohistochemistry (IHC) assay detects overexpression of the c-Met protein, present in up to 50% of advanced NSCLC patients.
Designed according to FDA guidelines, the assay identifies patients who may benefit from MET-targeted therapies, such as AbbVie’s recently approved Emrelis (telisotuzumab vedotin-tllv).
The test complements NeoGenomics’ PanTracer portfolio, enhancing its comprehensive NSCLC testing capabilities and supporting precision oncology.
NeoGenomics, a US-based cancer genetics company, also recently gained conditional approval for two next-generation sequencing tests: the Neo Comprehensive Solid Tumor assay and NeoTYPE DNA & RNA Lung.
28-05-2025
📰 Recent News
- FDA Approves Abbott’s Minimally Invasive TMVR System for Mitral Valve Disease
- SAGA Diagnostics Launches Pathlight Multi-Cancer MRD Test in U.S.
- Oxford Brain Diagnostics Begins U.S. Rollout of Dementia Detection Software
- Roche and Broad Clinical Labs Collaborate to Advance SBX Sequencing Technology
- NeoGenomics Launches c-MET Companion Diagnostic for NSCLC
- ReGelTec’s Hydrafil System Receives CE Mark for Disc Augmentation
- Terumo Neuro Introduces SOFIA 88 Neurovascular Catheter in the US
- Elucent’s EnVisio X1 System receives Breakthrough Status from FDA
- Intalight's DREAM OCT Gains CE Mark for EU Launch
- GE HealthCare secures CE mark and FDA clearance for deep learning tech